Zhang H, Chen J, Meng Y, Cen Q, Wang H, Ding X
Cancer Gene Ther. 2024; 32(1):22-37.
PMID: 39511416
DOI: 10.1038/s41417-024-00845-w.
Wang S, Wang S, Pan W, Yi Y, Lu J
PLoS Comput Biol. 2024; 20(9):e1012444.
PMID: 39255326
PMC: 11414978.
DOI: 10.1371/journal.pcbi.1012444.
Chen Y, Bhaskara G, Lu Y, Lin K, Dent S
Genes Dev. 2024; 38(15-16):738-754.
PMID: 39168636
PMC: 11444170.
DOI: 10.1101/gad.351789.124.
Zhang F, Chen X, Wang H, Guo T, Yao J, Jiang Z
BMC Med Genomics. 2024; 17(1):164.
PMID: 38898455
PMC: 11186196.
DOI: 10.1186/s12920-024-01937-0.
Chen Y, Bhaskara G, Lu Y, Lin K, Dent S
bioRxiv. 2024; .
PMID: 38585845
PMC: 10996596.
DOI: 10.1101/2024.03.26.586811.
CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1.
Pfeiffer C, Grandits A, Asnagli H, Schneller A, Huber J, Zojer N
Leukemia. 2023; 38(1):181-192.
PMID: 37898670
DOI: 10.1038/s41375-023-02071-z.
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.
Cardona-Benavides I, Misiewicz-Krzeminska I, Rojas E, de Ramon C, Sanz-Solas A, Isidro I
Haematologica. 2023; 109(3):877-887.
PMID: 37646661
PMC: 10905080.
DOI: 10.3324/haematol.2023.283445.
UBE2C promotes leptomeningeal dissemination and is a therapeutic target in brain metastatic disease.
Paisana E, Cascao R, Custodia C, Qin N, Picard D, Pauck D
Neurooncol Adv. 2023; 5(1):vdad048.
PMID: 37215954
PMC: 10195208.
DOI: 10.1093/noajnl/vdad048.
Comprehensive analysis of prognosis of cuproptosis-related oxidative stress genes in multiple myeloma.
Li T, Yao L, Hua Y, Wu Q
Front Genet. 2023; 14:1100170.
PMID: 37065484
PMC: 10102368.
DOI: 10.3389/fgene.2023.1100170.
A novel prognostic model based on pyroptosis-related genes for multiple myeloma.
Zhang C, Wu S, Chen B
BMC Med Genomics. 2023; 16(1):32.
PMID: 36823654
PMC: 9948482.
DOI: 10.1186/s12920-023-01455-5.
Artificial Intelligence Predicted Overall Survival and Classified Mature B-Cell Neoplasms Based on Immuno-Oncology and Immune Checkpoint Panels.
Carreras J, Roncador G, Hamoudi R
Cancers (Basel). 2022; 14(21).
PMID: 36358737
PMC: 9657332.
DOI: 10.3390/cancers14215318.
AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity.
Bloedjes T, de Wilde G, Khan G, Ashby T, Shaughnessy J, Zhan F
Blood Adv. 2022; 7(9):1697-1712.
PMID: 36322819
PMC: 10182179.
DOI: 10.1182/bloodadvances.2022007383.
Systematic Pan-Cancer Analysis Identifies CDK1 as an Immunological and Prognostic Biomarker.
Yang Y, Liu Q, Guo X, Yuan Q, Nian S, Kang P
J Oncol. 2022; 2022:8115474.
PMID: 36090896
PMC: 9452984.
DOI: 10.1155/2022/8115474.
AATF/Che-1 localizes to paraspeckles and suppresses R-loops accumulation and interferon activation in Multiple Myeloma.
Bruno T, Corleone G, Catena V, Cortile C, De Nicola F, Fabretti F
EMBO J. 2022; 41(22):e109711.
PMID: 35929179
PMC: 9670196.
DOI: 10.15252/embj.2021109711.
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Heynen G, Baumgartner F, Heider M, Patra U, Holz M, Braune J
Blood Adv. 2022; 7(4):469-481.
PMID: 35917568
PMC: 9979771.
DOI: 10.1182/bloodadvances.2022007875.
A same-day assay predicts apoptotic response to combined BCL-2 and MCL-1 BH3-mimetic targeting in multiple myeloma cells.
Grundy M, Al-Kaisi F, Cull J, Williams C, Smith D, Seedhouse C
EJHaem. 2022; 2(1):40-47.
PMID: 35846088
PMC: 9175957.
DOI: 10.1002/jha2.133.
Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles.
Borisov N, Sergeeva A, Suntsova M, Raevskiy M, Gaifullin N, Mendeleeva L
Front Oncol. 2021; 11:652063.
PMID: 33937058
PMC: 8083158.
DOI: 10.3389/fonc.2021.652063.
CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia.
Liu W, Yi J, Liu Y, Chen C, Zhang K, Zhou C
Front Genet. 2021; 11:600227.
PMID: 33597968
PMC: 7882723.
DOI: 10.3389/fgene.2020.600227.
Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma.
Bruno T, De Nicola F, Corleone G, Catena V, Goeman F, Pallocca M
Blood Adv. 2020; 4(22):5616-5630.
PMID: 33186461
PMC: 7686885.
DOI: 10.1182/bloodadvances.2020002566.
AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma.
Bloedjes T, de Wilde G, Maas C, Eldering E, Bende R, van Noesel C
Blood Adv. 2020; 4(17):4151-4164.
PMID: 32898245
PMC: 7479958.
DOI: 10.1182/bloodadvances.2019001393.
